The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency.
Fiche publication
Date publication
janvier 2021
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LE NAOUR Richard
Tous les auteurs :
Robbins A, Bahuaud M, Hentzien M, Maestraggi Q, Barbe C, Giusti D, Le Naour R, Batteux F, Servettaz A
Lien Pubmed
Résumé
Patients with primary humoral immunodeficiency are more prone to invasive as well as recurrent pneumococcal infections. Therefore, anti-pneumococcal vaccination including the 13-valent conjugate vaccine is recommended. Nevertheless, to date, no data is available on immunogenicity of this vaccine in this population.
Mots clés
IgG subclass deficiency, common variable immunodeficiency, conjugate vaccination, pneumococcal vaccine, primary humoral immunodeficiency
Référence
Front Immunol. 2021 ;12:697128